DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
AZD9291 is an investigational drug.
There have been 74 clinical trials for AZD9291. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.
There are one hundred and sixty-seven US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for AZD9291
|Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer||M.D. Anderson Cancer Center||Phase 1/Phase 2|
|Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib||Cancer Institute and Hospital, Chinese Academy of Medical Sciences||Phase 2|
Top disease conditions for AZD9291
Top clinical trial sponsors for AZD9291
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AZD9291||⤷ Try it Free||Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)||Yeda Research and Development Co. Ltd. (Rehovot, IL)||⤷ Try it Free|
|AZD9291||⤷ Try it Free||2-(2,4,5-substituted-anilino)pyrimidine compounds||AstraZeneca AB (Sodertalje, SE)||⤷ Try it Free|
|AZD9291||⤷ Try it Free||Nuclear medicine diagnostic imaging agent||Kyoto University (Kyoto, JP) ARKRAY, Inc. (Kyoto, JP)||⤷ Try it Free|
|AZD9291||⤷ Try it Free||Compositions comprising bacterial strains||4D Pharma Research Limited (GB)||⤷ Try it Free|
|AZD9291||⤷ Try it Free||Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use||Signal Pharmaceuticals, LLC (San Diego, CA)||⤷ Try it Free|
|AZD9291||⤷ Try it Free||COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers||REILEY PHARMACEUTICALS, INC. (San Jose, CA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AZD9291||Australia||AU2015313811||2034-09-08||⤷ Try it Free|
|AZD9291||Canada||CA2959775||2034-09-08||⤷ Try it Free|
|AZD9291||European Patent Office||EP3176183||2034-09-08||⤷ Try it Free|
|AZD9291||European Patent Office||EP3191523||2034-09-08||⤷ Try it Free|
|AZD9291||Japan||JP2017534574||2034-09-08||⤷ Try it Free|
|AZD9291||World Intellectual Property Organization (WIPO)||WO2016038610||2034-09-08||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|